Federal Circuit IP Digest
Federal Circuit Strikes Down Mondis Patent for Lack of Written Description
August 8, 2025
Mondis Tech. Ltd. v. LG Elecs. Inc Authored by: Jeremy J. Gustrowsky In a significant decision for patent law, the Federal Circuit Court of Appeals reversed a $14.3 million damages award against LG Electronics, holding that key claims of U.S.…
Read MorePatent Owner’s Deletion of “Stability” Limits Claim Scope in Insecticide Patent Dispute
August 1, 2025
FMC Corp. v. Sharda USA, LLC Authored by: Jeremy J. Gustrowsky In FMC Corp. v. Sharda USA, LLC, the Federal Circuit vacated a preliminary injunction that had barred Sharda from selling its insecticide product, finding that the lower court misinterpreted…
Read MoreFederal Circuit Orders New Trial on LED Tube Lamp Patents After Exclusion of Key Evidence
July 28, 2025
Jiaxing Super Lighting Elec. Appliance, Co., v. CH Lighting Tech. Co Authored by: Jeremy J. Justrowsky In a significant patent dispute over LED tube lamp technology, the Federal Circuit has sent the case of Jiaxing Super Lighting Electric Appliance Co.,…
Read MoreFederal Circuit Dodges Patent Royalty Battle, Transfers Case Over Jurisdiction Hiccup
July 25, 2025
Acorda Therapeutics, Inc. v. Alkermes PLC Authored by: Jeremy J. Gustrowsky In the world of pharmaceutical partnerships, Acorda Therapeutics and Alkermes PLC once teamed up to bring Ampyra—a drug helping multiple sclerosis patients walk better—to market. Alkermes held a key…
Read MoreSunkist Prevails in Trademark Dispute Over “KIST” Soda Branding
July 23, 2025
Sunkist Growers, Inc. v. Intrastate Distribs., Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the U.S. Court of Appeals for the Federal Circuit reversed a ruling by the Trademark Trial and Appeal Board (TTAB) and sided with Sunkist…
Read MoreFederal Circuit Clarifies Limits of Interference Estoppel in Patent Reviews: IGT v. Zynga
July 22, 2025
IGT v. Zynga Inc Authored by: Jeremy J. Gustrowsky In a significant decision for patent litigation and the gaming industry, the Federal Circuit affirmed the unpatentability of several claims in IGT’s U.S. Patent No. 7,168,089, which covers secure software transfers…
Read MorePatent Infringement Win Overturned: Colibri Heart Valve Loses $106 Million Verdict Against Medtronic
July 18, 2025
Colibri Heart Valve LLC v. Medtronic Corevalve, LLC Authored by: Jeremy J. Gustrowsky In a significant patent law decision, the Federal Circuit reversed a $106 million jury verdict in favor of Colibri Heart Valve LLC against Medtronic CoreValve, LLC, ruling…
Read MoreFederal Circuit Clarifies Use of Applicant Admitted Prior Art in Patent Challenges
July 14, 2025
Shockwave Med., Inc. v. Cardiovascular Sys Authored by: Jeremy J. Gustrowsky In the recent case of Shockwave Medical, Inc. v. Cardiovascular Systems, Inc., the Federal Circuit addressed how “Applicant Admitted Prior Art” (AAPA) can be used in patent challenges before…
Read MoreFederal Circuit Upholds Janssen’s Invega Sustenna Patent Against Obviousness Challenge
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a significant decision for pharmaceutical patent holders, the Federal Circuit has affirmed the validity of Janssen Pharmaceuticals’ U.S. Patent No. 9,439,906, which covers specific dosing regimens…
Read MoreFederal Circuit Clarifies Obviousness Standards for Drug Dosing Patents
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit provided important guidance on how courts should analyze the obviousness of pharmaceutical dosing regimen patents. The case involved Janssen’s U.S.…
Read MoreFederal Circuit Affirms Cisco’s Win Over Egenera in Virtual Network Patent Dispute
July 7, 2025
Egenera, Inc. v. Cisco Sys., Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit upheld a district court’s ruling that Cisco Systems, Inc. did not infringe Egenera, Inc.’s U.S. Patent No. 7,231,430, which covers technology for…
Read MoreFederal Circuit Narrows “Consisting Essentially Of” in Eye Therapies v. Slayback Pharma Patent Dispute
June 30, 2025
Eye Therapies, LLC v. Slayback Pharma, LLC Authored by: Jeremy J. Gustrowsky In a significant decision for patent claim interpretation, the Federal Circuit recently reversed a Patent Trial and Appeal Board (PTAB) ruling in Eye Therapies, LLC v. Slayback Pharma,…
Read More